3Wiliam F, Keane, Barry M, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the R ENAAL study. Kidney Int, 2003, 63 (4) :1499 -1507.
4Kelly D J, Buck D, Cox A J, et al. Effects on protein kinase C-beta inhibition on glomerular vascular endothehal growth factor expression and endothelial cells in advanced experimental diabetic nephropathy. Am J Physiol Renal Physiol, 2007, 293 ( 2 ) : F565 - 74.
5Forbes JM, Fukami K, Cooper ME, et al. Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes, 2007, 115(2) :69 -84.
6Matsumae T, Jimi S, Uesugi N, et al. Clinical and morphometrical interrelationships in patients with overt nephropathy induced by non- insulin-dependent diabetes mellitus. A light- and electron-microscopy study. Nephron, 1999 Jan ;81 ( 1 ) :41 - 48.
7White KE, Bilious RW. Estimation of podocyte number: A comparison of methods. Kidney Int, 2004, 66 (2) : 663 - 667.
8van den Berg JG, van den Bergh Weerman MA, Assmann KJ, et al. Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. Kidney Int, 2004, 66 ( 5 ) : 1901 - 1906.
9Lane PH, Steffes MW, Mauer SM. Estimation of glomerular volume : a comparison of four methods. Kidney Int, 1992, 41 (4) : 1085 - 1089.
10Dalla Vestra M, Masiero A, Roiter AM, et al. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabtes. Diabetes, 2003, 52(4) : 1031 - 1035.
